Literature DB >> 14649311

A different molecular pattern of beta-thalassemia mutations in northeast Brazil.

Aderson S Araújo1, l Wilson A Júnior Silva, Silvana A C Leão, Flavia C G M Bandeira, Mary Petrou, Bernadette Modell, Marco A Zago.   

Abstract

The main hereditary hemoglobin (Hb) disorders of clinical significance in Brazil are sickle cell disease and beta-thalassemia (thal). The sickle gene was introduced by the slave trade, whereas beta-thal was introduced later, due to a massive immigration (mostly by Italians) between 1870 and 1953, mainly to the southeast region of Brazil. Molecular studies performed in the southeast of the country showed a marked prevalence of the nonsense mutation at codon 39 (C --> T) (47-54%), leading to severe forms of beta0-thal. However, the northeast region of the country has a different demographic history, characterized by the absence of the massive Italian immigration. Owing to this and since the majority of cases of beta-thal in Pernambuco, a state located in the northeast of the country, have mild or intermediate clinical and laboratory features, we would predict a different spectrum of beta-thal mutations in this region. We examined 60 unrelated patients (86 beta-thal chromosomes) under regular clinical follow-up in Pernambuco: 6 were regularly transfused beta-thal major subjects, 20 had beta-thal intermedia, 20 had Hb S/beta-thal and 14 were beta-thal trait individuals. The following mutations were found: IVS-I-6 (T --> C) 62.8%, IVS-I-1 (G -->A) 15.1%, IVS-I-5 (G --> C) 9.3%, IVS-I-110 (G --> A) 8.2%, codon 39 (C --> T) 3.5%, and codon 30 (AGG --> AGC) 1.1%. These data show different patterns of beta-thal mutations in two regions of Brazil, demonstrating a thus far unrevealed heterogeneity of the disease in the country.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14649311     DOI: 10.1081/hem-120026045

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  5 in total

1.  Hb S/β-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, Laboratory and Molecular Characteristics.

Authors:  André R Belisário; Anna B Carneiro-Proietti; Ester Cerdeira Sabino; Aderson Araújo; Paula Loureiro; Cláudia Máximo; Miriam V Flor-Park; Daniela D O W Rodrigues; Mina Cintho Ozahata; Christopher McClure; Rosimere Afonso Mota; Isabel C Gomes Moura; Brian Custer; Shannon Kelly
Journal:  Hemoglobin       Date:  2020-03-16       Impact factor: 0.849

2.  Characterization of beta-thalassemia mutations in patients from the state of Rio Grande do Norte, Brazil.

Authors:  Zama Messala Luna da Silveira; Maria das Vitórias Barbosa; Thales Allyrio Araújo de Medeiros Fernandes; Elza Miyuki Kimura; Fernando Ferreira Costa; Maria de Fátima Sonati; Ivanise Marina Moretti Rebecchi; Tereza Maria Dantas de Medeiros
Journal:  Genet Mol Biol       Date:  2011-07-01       Impact factor: 1.771

3.  Anti-Toxoplasma gondii antibodies in patients with beta-hemoglobinopathies: the first report in the Americas.

Authors:  Marina Neves Ferreira; Claudia Regina Bonini-Domingos; Isabeth Fonseca Estevão; Clarice Lopes de Castro Lobo; Gisele Cristina Souza Carrocini; Aparecida Perpétuo Silveira-Carvalho; Octávio Ricci; Luiz Carlos de Mattos; Cinara Cássia Brandão de Mattos
Journal:  BMC Res Notes       Date:  2017-06-14

4.  Use of an automated pyrosequencing technique for confirmation of sickle cell disease.

Authors:  Camila Cruz de Martino; Cecilia Salete Alencar; Paula Loureiro; Anna Barbara de Freitas Carneiro-Proietti; Claudia de Alvarenga Máximo; Rosimere Afonso Mota; Daniela Oliveira Werneck Rodrigues; Nelson Gaburo Junior; Shannon Kelly; Ester Cerdeira Sabino
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

5.  Association of FOXO3 polymorphism (rs3800231) and clinical subphenotypes of beta thalassemic individuals.

Authors:  Flaviene F Torres; Victoria S Bernardo; Danilo G H Silva; Jéssika V Okumura; Claudia R Bonini-Domingos
Journal:  Hematol Transfus Cell Ther       Date:  2020-11-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.